Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients

Antiviral Therapy

Volumn 18, Issue 3, 2013, Pages 289-300

  Lathouwers, Erkki ^a   De La Rosa, Guy ^b   Van De Casteele, Tom ^a   Baeten, Benny ^a   Tomaka, Frank ^b   De Meyer, Sandra ^a   Picchio, Gaston ^b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RITONAVIR; SULFONAMIDES; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84878103808     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2569     Document Type: Article

References (20)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 10 January 2011. Accessed 11 September 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
2. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40:158-163. (Pubitemid 40053474)
3. European AIDS Clinical Society (EACS). Guidelines: clinical management of treatment of HIV infected adults in Europe. Version 5. (Updated November 2009. Accessed 12 September 2011.) Available from http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/version-5-november2009- eacs-guidelines-cologne.pdf
4. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
5. Orkin C, DeJesus E, Khanlou H, et al. ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naive HIV-1-infected adults. 10th International Congress on Drug Therapy in HIV Infection. 7-11 November 2010, Glasgow, UK. Abstract P3.
6. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25:929-939.
7. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. (Pubitemid 46541620)
8. Katlama C, Bellos N, Grinsztejn B, et al. POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir 600/100mg bid in treatment-experienced HIV patients. 9th International Congress on Drug Therapy in HIV Infection. 9-13 November 2008, Glasgow, UK. Abstract P21.
9. Pozniak A, Arasteh K, Molina J-M, et al. POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir 600/100mg bid in treatment-experienced HIV patients. 9th International Congress on Drug Therapy in HIV Infection. 9-13 November 2008, Glasgow, UK. Abstract P24.
10. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled Phase III trial. Lancet 2007; 370:49-58. (Pubitemid 47023100)
11. De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, de Béthune MP, Miralles GD. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr 2008; 49:179-182.
12. De La Rosa G, Pattery T, Picchio G, Lathouwers E, Villacian J, Van der Borght K. Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009. 10th International Congress on Drug Therapy in HIV Infection. 7-11 November 2010, Glasgow, UK. Abstract P132.
13. De Meyer S, Dierynck I, Lathouwers E, et al. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2. 16th International HIV Drug Resistance Workshop. 10-14 June 2008, Sitges, Spain. Abstract 31.
14. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
15. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-163.
16. Vandenbroucke I, Van Marck H, Mostmans W, et al. HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Res Ther 2010; 7:4.
17. de Meyer S, Vangeneugden T, Van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24:379-388. (Pubitemid 351457745)
18. De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23:1829-1840.
19. Lathouwers E, De Meyer S, Dierynck I, et al. Virological characterisation of patients failing DRV/r or LPV/r in the ARTEMIS study: 96 week analysis. Antivir Ther 2011; 16:99-108.
20. De Meyer S, Lathouwers E, Dierynck I, et al. Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients. 9th International Congress on Drug Therapy in HIV Infection. 9-13 November 2008, Glasgow, UK. Abstract 0424.